We evaluated the in vitro activity of delafloxacin against a panel of 117 Neisseria gonorrhoeae strains, including 110 clinical isolates collected from 2012 to 2015 and seven reference strains, compared with the activities of seven antimicrobials currently or previously recommended for treatment of gonorrhea. We examined the potential for delafloxacin to select for resistant mutants in ciprofloxacin-susceptible and ciprofloxacin-resistant N. gonorrhoeae. We characterized mutations in the gyrA, gyrB, parC, and parE genes and the multidrug-resistant efflux pumps (MtrC-MtrD-MtrE and NorM) by PCR and sequencing and by wholegenome sequencing. The MIC 50 , MIC 90 , and MIC ranges of delafloxacin were 0.06 g/ml, 0.125 g/ml, and <0.001 to 0.25 g/ ml, respectively. The frequency of spontaneous mutation ranged from 10 ؊7 to <10 ؊9 . The multistep delafloxacin resistance selection of 30 daily passages resulted in stable resistant mutants. There was no obvious cross-resistance to nonfluoroquinolone comparator antimicrobials. A mutant with reduced susceptibility to ciprofloxacin (MIC, 0.25 g/ml) obtained from the ciprofloxacin-susceptible parental strain had a novel Ser91Tyr alteration in the gyrA gene. We also identified new mutations in the gyrA and/or parC and parE genes and the multidrug-resistant efflux pumps (MtrC-MtrD-MtrE and NorM) of two mutant strains with elevated delafloxacin MICs of 1 g/ml. Although delafloxacin exhibited potent in vitro activity against N. gonorrhoeae isolates and reference strains with diverse antimicrobial resistance profiles and demonstrated a low tendency to select for spontaneous mutants, it is important to establish the correlation between these excellent in vitro data and treatment outcomes through appropriate randomized controlled clinical trials.
G
onorrhea is the second most commonly reported notifiable disease in the United States, with a total of 333,004 cases reported to the Centers for Disease Control and Prevention (CDC) in 2013 (1) . The World Health Organization (WHO) estimates that 106.1 million new cases of gonococcal infections are diagnosed annually worldwide (2) . Untreated gonorrhea can cause serious complications, including pelvic inflammatory disease, infertility, ectopic pregnancy, and chronic pelvic pain in women and epididymitis and infertility in men (3) . Gonorrhea has also been shown to increase the risk of contracting and transmitting HIV (4) .
For several decades, the global gonorrhea control and prevention strategy has relied heavily on recommendations of effective antimicrobials for empirical treatment of gonorrhea but the ability of Neisseria gonorrhoeae to develop antimicrobial resistance has persistently posed a great challenge to selection of effective therapies (5) . N. gonorrhoeae has progressively and consistently developed resistance to all antimicrobials previously recommended for first-line treatments of gonorrhea, including sulfonamides, penicillins, tetracyclines, fluoroquinolones, macrolides, and recently, extended-spectrum cephalosporins, the last remaining first-line treatment option for gonorrhea (5) . This sequential development of gonococcal antimicrobial resistance has led to a drastic reduction in the number of effective antimicrobials available for gonorrhea treatment. There is a growing public health concern that gonorrhea may become untreatable in certain circumstances. CDC now recommends only dual therapy with ceftriaxone (250 mg intramuscularly [IM] ) plus a single oral dose of azithromycin (1 g orally) for treatment of all gonococcal infections (6) . New effective antimicrobial agents and novel drug regimens are urgently needed to treat gonococcal infections, including those caused by multidrug-resistant (MDR) N. gonorrhoeae.
Delafloxacin, a novel fluoroquinolone (developed as RX-3341 [by Rib-X Pharmaceuticals Inc., now Melinta Therapeutics, New Haven, CT]; formerly known as WQ-3034 [Wakunaga Pharmaceutical Co., Hiroshima, Japan] and ABT-492 [Abbott Laboratories, Abbott Park, IL, USA]), has shown promising in vitro potency against a wide range of bacteria and improved activity in acidic environments (7) . However, there are limited data on the activity of delafloxacin against N. gonorrhoeae and selection of gonococcal delafloxacin resistance. In this study, we evaluated the in vitro potency of delafloxacin, relative to the in vitro activities of antimicrobials previously or currently used for treatment of gonorrhea, against clinical N. gonorrhoeae isolates collected from 2012 to 2015; determined the potential for delafloxacin to select for resistant mutants in ciprofloxacin-susceptible and ciprofloxacin-resistant N. gonorrhoeae strains; and characterized mutations in the gyrA, gyrB, parC, and parE genes and in multidrug-resistant efflux pumps (MtrC-MtrD-MtrE and NorM).
MATERIALS AND METHODS
Bacterial strains. We selected a panel of 117 N. gonorrhoeae strains, including clinical isolates collected from 2012 to 2015 (n ϭ 110) and the CDC Gonococcal Isolate Surveillance Project (GISP) reference strains (n ϭ 7), with various levels of resistance and susceptibility to antimicrobials previously or currently recommended for gonorrhea treatment. The clinical N. gonorrhoeae isolates were from diverse anatomic sites and included urethral, pharyngeal, rectal, vaginal, and endocervical isolates collected from patients in seven cities in the United States. The urethral N. gonorrhoeae strains were collected from patients attending publicly funded sexually transmitted disease (STD) clinics as part of the CDCsupported national surveillance program that monitors trends in the antimicrobial susceptibilities of N. gonorrhoeae in the United States (8) . Seven GISP reference strains with established MIC ranges for various antimicrobials were included for quality control of antimicrobial susceptibility testing (AST). All clinical N. gonorrhoeae isolates were confirmed by standard biochemical methods and stored at Ϫ80°C as described previously (9) .
Antimicrobial susceptibility testing. MICs of delafloxacin and comparator antimicrobials were determined by the Clinical and Laboratory Standards Institute (CLSI)-recommended agar dilution method (10) . The activity of delafloxacin was compared with that of 7 comparator antimicrobials (penicillin, tetracycline, cefixime, ceftriaxone, ciprofloxacin, azithromycin, and spectinomycin). MICs were interpreted according to the CLSI criteria when available (10) . CLSI resistance breakpoints were used for penicillin (Ն2.0 g/ml), tetracycline (Ն2.0 g/ml), spectinomycin (Ն128.0 g/ml), and ciprofloxacin (Ն1.0 g/ml) (10). We used GISP breakpoints for azithromycin (Ն2.0 g/ml), cefixime (Ն0.25 g/ml), and ceftriaxone (Ն0.125 g/ml) (11), because CLSI has not established criteria for resistance to these antimicrobials. We defined multidrug resistance as resistance to Ն3 antimicrobial classes as recommended by Falagas and Karageorgopoulos (12) . There are no established N. gonorrhoeae susceptibility or resistance breakpoints for delafloxacin.
Single-step selection of delafloxacin-resistant mutants. Four clinical N. gonorrhoeae strains, including three ciprofloxacin-resistant strains (ciprofloxacin MIC values of 2, 16, and 32 g/ml, respectively), and one ciprofloxacin-susceptible N. gonorrhoeae strain (ciprofloxacin MIC value of 0.015 g/ml) were used to evaluate the potential for delafloxacin to develop spontaneous mutants in a single-step resistance selection procedure as described previously (13, 14) . Aliquots (1 and 0.1 ml) of the inoculum suspensions were plated onto two sets of GC medium base (Difco Laboratories, Becton, Dickinson and Company, Sparks, MD, USA) supplemented with 1% BBL IsoVitaleX enrichment (Becton, Dickinson and Company) (GCMBI) agar plates containing 2ϫ, 4ϫ, 8ϫ, and 16ϫ the MIC of delafloxacin. Colony counts of the mutant population, including all variants, were determined after 24 and 48 h of incubation. Serial dilutions of the original inoculum suspension were plated in duplicate onto drug-free GCMBI agar plates, and colony counts were averaged to determine the total number of viable N. gonorrhoeae colonies per inoculum. The frequency of spontaneous resistance selected at each delafloxacin concentration (2ϫ, 4ϫ, 8ϫ, and 16ϫ the respective original MICs) was determined as the ratio corresponding to the number of mutants divided by the number of bacteria in the original inoculum. The strength of an antibiotic for which a resistant colony was not observed after 48 h of incubation was assigned a frequency-of-mutation value lower than the reciprocal of the total number of viable bacteria plated as described previously (13) . All tests were performed in triplicate.
Delafloxacin multistep resistance selection. The four clinical N. gonorrhoeae strains described above were used to evaluate the potential for delafloxacin to select for resistant N. gonorrhoeae mutants in a multistep resistance selection involving 30 daily passages in subinhibitory concentrations of delafloxacin as described previously (15, 16) . The N. gonorrhoeae identities of the resistant mutants were confirmed by Gram staining, oxidase test, superoxol test (catalase test using 30% H 2 O 2 ), and Phadebact monoclonal GC test (MKL Diagnostics AB, Sollentuna, Sweden). After the last passage, resistant mutants were passaged 10 times in drug-free GCMBI agar and chocolate agar to confirm the stability of the selected resistance phenotypes. Agar dilution AST was performed on the four parental N. gonorrhoeae strains, resistant mutants derived from 30 daily passages, and mutants passaged 10 times in drug-free agar plates.
Characterization of resistance mutations. DNA samples were extracted from the parental strains and resistant mutants. We amplified the gyrA, gyrB, parC, and parE and the efflux mtrR genes by PCR using published primers and cycling parameters (14, (17) (18) (19) . PCR products were purified and subjected to bidirectional sequencing at the University of Washington High-Throughput Genomics Center. The nucleotide sequences were assembled, and the resulting amino acid sequences were compared with corresponding sequences of N. gonorrhoeae strain FA 1090 (GenBank accession number AE004969) using Vector NTI (Invitrogen/ Thermo Fisher Scientific Inc., Waltham, MA). WHO N. gonorrhoeae reference strain WHO K was used for quality control of PCR and sequencing (19) .
Whole-genome sequencing and data analysis. Whole-genome sequencing and bioinformatics analysis of genomic data were performed at the University of Washington, Department of Laboratory Medicine. DNA extraction and library preparation were performed as described previously (20) , with the addition of a size selection step to enrich for library fragments 700 to 900 bp in size. Whole-genome sequencing was performed on a MiSeq instrument (Illumina, San Diego, CA) using 250-bp paired-end reads. Sequence reads were processed, aligned to the N. gonorrhoeae FA 1090 reference genome, and subjected to variant calling as described previously (20) , except that bwa mem (v0.7.12) (21) and samtools (v.1.1) (22) were used, and the identified variants were required to be supported by 5 reads or more with a likelihood score of 125 or greater. Variant functions were annotated using SnpEFF (v4.1G) (23) .
RESULTS
Activity of delafloxacin and comparator antimicrobials. Delafloxacin exhibited excellent in vitro activity against 117 N. gonorrhoeae strains (110 clinical N. gonorrhoeae isolates and 7 GISP reference strains). In general, MICs of delafloxacin (Յ0.001 to 0.25 g/ml) were lower than those of 5 comparator antimicrobials but comparable to those of ceftriaxone (Յ0.001 to 0.25 g/ml) and cefixime (Յ0.001 to 0.5 g/ml) ( Table 1 ). The highest delafloxacin MIC observed was 0.25 g/ml in a single clinical isolate. High percentages of resistance were observed for ciprofloxacin, a fluoroquinolone comparator antimicrobial (67.5%), and other antimicrobials previously or currently recommended for gonor- a R*/RS*, resistance/reduced susceptibility; ND, not determined (breakpoints have not been established). Percentages of resistance were calculated for penicillin (Ն2 g/ml), tetracycline (Ն2 g/ml), azithromycin (Ն2 g/ml), and spectinomycin (Ն128 g/ml). Percentages of reduced susceptibility were calculated for cefixime (Ն0.25 g/ml) and ceftriaxone (Ն0.125 g/ml).
rhea treatment, including tetracycline (69.2%), penicillin (59%), and azithromycin (16.2%); 3 clinical isolates showed high-level azithromycin resistance (azithromycin MIC, Ͼ512 g/ml). In addition, 33 (28.2%) of the gonococcal strains exhibited reduced susceptibility to cefixime (MIC, Ն0.25 g/ml), with 14 of those strains demonstrating concurrent reduced susceptibility to ceftriaxone (MIC, Ն0.125 g/ml). Sixty-seven (57.3%) N. gonorrhoeae strains were resistant to penicillin, tetracycline, and ciprofloxacin (MDR), with 29 of the MDR strains exhibiting concurrent reduced susceptibility to cefixime (MIC, Ն0.25 g/ml) and 14 with reduced susceptibility to both cefixime and ceftriaxone. No clinical isolate or reference strain was resistant to spectinomycin except the GISP spectinomycin-resistant reference strain included for quality control. The MIC range, MIC 50 , and MIC 90 of delafloxacin were Յ0.001 to 0.25 g/ml, 0.06 g/ml, and 0.125 g/ml, respectively, compared to the MIC range, MIC 50 , and MIC 90 of ciprofloxacin, which were 0.004 to Ͼ16 g/ml, 4, and 16 g/ml, respectively. The MIC 50 (4 g/ml) and MIC 90 (16 g/ml) for ciprofloxacin were 64-fold and 128-fold, respectively, higher than those of delafloxacin ( Table 1 ). The MIC distributions showing the activity of delafloxacin against 117 N. gonorrhoeae strains compared with the activity of ciprofloxacin are presented in Fig. 1 . Single-step resistance selection mutation frequency. The mutation frequency was below the limit of detection for ciprofloxacin-resistant N. gonorrhoeae strain 1315 at all concentrations tested (Ͻ2 ϫ 10 Ϫ9 ). Although resistant mutants arose at a frequency between 1.7 ϫ 10 Ϫ7 and 8.9 ϫ 10 Ϫ8 at 2ϫ the original delafloxacin MICs for the other two ciprofloxacin-resistant N. gonorrhoeae strains (13199 and 131011), the mutation frequencies were below the limit of detection at 4ϫ, 8ϫ, and 16ϫ the MIC (Ͻ1.4ϫ10 Ϫ9 to Ͻ1.6ϫ10 Ϫ9 ) ( Table 2 ). The frequency of selection of spontaneous mutants for ciprofloxacin-susceptible strain 13212 ranged from 1.8 ϫ10 Ϫ7 (16ϫ MIC) to 4.6 ϫ10 Ϫ7 (2ϫ MIC) ( Table 2) .
Multistep delafloxacin resistance selection. The multistep delafloxacin resistance selection of 30 daily passages resulted in mutants with 8-fold to 16-fold increases in delafloxacin MICs (Table  3) . Mutant clones from each strain had the same morphology and were confirmed to have the same susceptibility profiles by performing AST on five distinct clones. The MICs of seven comparator antimicrobials for parental and mutant strain pairs were exactly the same or within Ϯ 1 log 2 dilution, suggesting lack of cross-resistance (Table 3) , except for the mutants derived from ciprofloxacin-susceptible strain 13212, which had a 16-fold increase in the ciprofloxacin MIC from 0.015 g/ml to 0.25 g/ml.
There was no decrease in delafloxacin MICs for the mutants after they were passaged 10 times in drug-free GCMBI agar and chocolate agar, confirming the stability of resistance phenotypes (Table 3) . Analysis of resistance mutations. All the three ciprofloxacinresistant strains harbored previously described double mutations in the gyrA gene and a single mutation in the parC gene (17, 18, 24) . The presence of triple mutations was consistent in the parental strains and their resistant mutants. For these 3 strains, GyrA changes occurred at positions 91 and 95 with substitutions of 
Ϫ9
a The mutation frequency was calculated as the number of resistant colonies per inoculum. The strength of an antibiotic for which a resistant colony was not observed after 48 h of incubation was assigned a frequency-of-mutation value lower than the reciprocal of the total number of viable organisms plated as described previously (13) . ID, identification number.
Ser91Phe, Asp95Ala, Asp95Asn, and Asp95Gly. Mutations in the quinolone resistance-determining region (QRDR) of the parC gene occurred at positions 86, 87, and 91, with different substitutions correlated with the level of fluoroquinolone resistance found among the three ciprofloxacin-resistant parental strains and the delafloxacin-resistant mutants, Asp86Asn (low-level ciprofloxacin resistance), Ser87Ile, and Glu91Gly (high-level ciprofloxacin resistance) (17, 24) . All these changes were found in both the parental strains and the selected resistant mutants (Table 4) . Interestingly, phenotypic cross-resistance to ciprofloxacin which was well correlated with the genotypic data was observed for the mutant derived from N. gonorrhoeae strain 13212. The ciprofloxacin-susceptible parental strain (MIC, 0.015 g/ml) did not harbor any mutations in the QRDR, whereas the mutant with reduced susceptibility to ciprofloxacin (MIC, 0.25 g/ml) had a novel Ser91Tyr alteration in the gyrA gene. Single gyrA changes have been previously shown to be correlated with ciprofloxacin MICs in the range of 0.125 to 1 g/ml (24) . To expand the scope of our analysis, we examined the entire coding sequence of the QRDR genes using whole-genome sequencing to identify novel mutations present specifically in the mutant strains, as well as characterizing mutations in the multidrug-resistant efflux pumps (MtrC-MtrD-MtrE and NorM). In the mutant strain of 13199, a disruptive 3-bp in-frame deletion in gyrA and a duplication of Ala at position 257 (Ala257dup) in parC were additionally detected. The mutant strain of 1315 carried multiple, previously unreported mutations in parC, parE, mtrD, and mtrE and in norM, and previously reported mutations in the promoter and the coding region of the mtrR were also identified. The high burden of mutations in the evolved strain of 1315 suggests that it could represent a strain exhibiting hypermutability (25) . We did not identify any novel mutations in the examined genes for the resistant mutants derived from strains 13212 and 131011.
DISCUSSION
In this study, delafloxacin demonstrated potent in vitro activity against a panel of 117 N. gonorrhoeae strains with diverse antimicrobial susceptibility profiles, including ciprofloxacin-resistant, multidrug-resistant, and contemporary isolates with high-level resistance to azithromycin and with reduced susceptibilities to cefixime (28.2%) and ceftriaxone (12%). The MIC 50 and MIC 90 of delafloxacin were 64 to 128 times lower than those of ciprofloxacin and were also lower than those of the other antimicrobials evaluated except for ceftriaxone and cefixime, which had comparable in vitro activities. These findings concur with data from a previous study from the CDC Laboratory Reference and Research Branch examining the susceptibility of delafloxacin among 93 N. gonorrhoeae isolates, including 73% that were ciprofloxacin resistant (26) . The MIC range, MIC 50 , and MIC 90 of delafloxacin obtained from the CDC's study were Յ0.002 to 0.5 g/ml, 0.06 g/ ml, and 0.125 g/ml, respectively, compared to the MIC range, MIC 50 , and MIC 90 of ciprofloxacin, which were Յ0.002 to 64 g/ ml, 8 g/ml, and 32 g/ml (26) . The data from CDC were comparable to the data from this study: MIC range of Յ0.001 to 0.25 g/ml, MIC 50 of 0.06 g/ml, and MIC 90 of 0.125 g/ml, compared to the MIC range, MIC 50 , and MIC 90 of ciprofloxacin, which were 0.004 to Ͼ16 g/ml, 4 g/ml, and 16 g/ml, respec- tively. The promising in vitro potency of delafloxacin compared with other fluoroquinolones has been associated with the specific shape, size, and polarity of the delafloxacin molecule (27) . Delafloxacin is also uniquely an anionic fluoroquinolone which lacks a positively charged substituent in position 7, possibly accounting for its ability to accumulate at much greater levels in both bacteria and eukaryotic cells at acidic pH (28) . Studies have shown that delafloxacin exhibits potent antimicrobial activity against a wide range of bacteria, including Staphylococcus aureus (methicillin-susceptible and methicillin-resistant strains), Streptococcus pneumoniae, Clostridium difficile, N. gonorrhoeae, Haemophilus influenzae, and Moraxella catarrhalis (26, (29) (30) (31) (32) (33) . Recently, delafloxacin was designated a qualified infectious disease product for treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia by the U.S. Food and Drug Administration (www.fda.gov).
The low level of selection of spontaneous mutants (10 Ϫ7 to Ͻ10 Ϫ9 ) by delafloxacin observed in this study concurs with findings from a previous study which reported that five fluoroquinolones (ciprofloxacin, levofloxacin, gemifloxacin, moxifloxacin, and trovafloxacin) selected resistant mutants at a lower frequency (10 Ϫ7 to 10 Ϫ9 ) in N. gonorrhoeae (13) . We selected resistant mutants with increased delafloxacin MICs, but there was a lack of cross-resistance to nonfluoroquinolone antimicrobials, including ceftriaxone and azithromycin, which are currently recommended for use as in dual therapy for gonorrhea treatment (6) . The highest delafloxacin MIC observed was 2 g/ml for resistant mutants from N. gonorrhoeae parental strain 131011. Delafloxacin resistance breakpoints for N. gonorrhoeae have not been established, and there are no published data to support delafloxacin achieving high pharmacokinetic-pharmacodynamic target attainment (PK-PD TA) rates for N. gonorrhoeae strains with elevated MICs (0.5 to 2.0 g/ml). It is noteworthy that, for ciprofloxacinsusceptible strain 13212, selection of an 8-fold increase in delafloxacin MIC, which was accompanied by concurrent reduced susceptibility to ciprofloxacin and a single gyrA mutation, may be of clinical significance. First-step target mutations associated with fluoroquinolone resistance have been reported to occur more often in the primary target enzyme (the GyrA subunit of DNA gyrase) in Gram-negative bacteria (34) , and single gyrA mutation has been correlated with an elevation of the fluoroquinolone MIC (35) .
A number of mutations were detected outside the well-characterized QRDR and in the multidrug-resistant efflux pumps by whole-genome sequencing. Interestingly, the spontaneous-mutation frequency for mutant strain 1315 with multiple mutations in parC, parE, mtrR, mtrD, and mtrE and norM was below the limit of detection. This is consistent with a previous study which failed to select resistant mutants upon exposure of hypermutable Escherichia coli to 4ϫ the MIC of a antimicrobial but successfully selected resistant mutants through continuous culture in the presence of sublethal concentrations of the antimicrobial (36) . The deletion of A in a 13-bp inverted repeat in the mtrR promoter and mutations (Asp79Asn, Thr86Ala, and His105Tyr) in the mtrR coding region have been previously reported to affect susceptibility to antimicrobials, including macrolides, ␤-lactams, cephalosporins, and ciprofloxacin, a fluoroquinolone (37) (38) (39) . However, the clinical relevance of the previously unreported mutations found in the mtrD and mtrE genes and in the norM gene of mutant strain 1315 is unclear. A recent study found that the delafloxacin MIC for a fluoroquinolone-susceptible N. gonorrhoeae strain was increased only minimally (from Ͻ0.0005 g/ml to 0.001 to 0.002 g/ml) due to mtrCDE mutations and also found that delafloxacin was not a substrate for the NorM efflux (40) . It is noteworthy that the 131011 mutant strain with the highest delafloxacin MIC (2 g/ml) did not have any novel mutations detected in the QRDR and efflux pumps, suggesting that resistance to delafloxacin involves, or at least can involve, previously uncharacterized mechanisms. Although a full characterization of the mechanism involved in the resistance pathway would be a worthwhile venture, it would require significant additional effort and is outside the scope of the current work.
In conclusion, delafloxacin was highly active against clinical N. gonorrhoeae isolates with diverse antimicrobial susceptibility profiles, including isolates with high-level ciprofloxacin resistance, high-level azithromycin resistance, reduced cephalosporin susceptibility, and multidrug resistance. However, findings from in vitro studies may not be entirely predictive of clinical outcomes (41) . Therefore, it is imperative to conduct rigorous clinical studies on the in vivo efficacy of delafloxacin against N. gonorrhoeae, including ciprofloxacin-resistant and multidrug-resistant strains from genital and extragenital (pharyngeal and rectal) sites, and to establish optimal dosing and safety and tolerability of delafloxacin and pharmacokinetic-pharmacodynamic indices correlating with therapeutic efficacy of delafloxacin for genital and extragenital gonococcal infections.
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